Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

Clonal cytogenetic evolution with additional chromosomal abnormalities (ACAs) in chronic
myelogenous leukemia (CML) is generally associated with decreased response to tyrosine …

This population-based registry was designed to provide robust and updated information on
the characteristics and the epidemiology of chronic myeloid leukemia (CML). All cases of …

Several guidelines and recommendations on the management of chronic myeloid leukemia
(CML) have been prepared by several scientific societies. The European LeukemiaNet …

Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL1 fusion
gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic …

Management of chronic myeloid leukemia (CML) in advanced phases remains a challenge
also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution …

Several papers authored by international experts have proposed recommendations on the
management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these …

Major route additional cytogenetic aberrations (ACA) at diagnosis of chronic myeloid
leukaemia (CML) indicate an increased risk of progression and shorter survival. Since major …

Chronic myeloid leukemia (CML) has been the first human malignancy to be associated,
more than 50 years ago, with a consistent chromosomal abnormality—the t (9; 22)(q34; q11) …